The U.K. drugmaker’s revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales. https://t.co/70Th3yj4fZ ...

AstraZeneca CFO Aradhana Sarin tells Anna Edwards how AI is transforming drug development and bringing medicines to patients faster https://t.co/mBO9IiUQQm https://t.co/OZ6HDNmjdh ...

DCC bought for £5.7 billion, Astra boosted by cancer drugs, Burnham to host Zelenskyy -- get briefed ahead of your morning calls with The London Rush https://t.co/x8ZNyfqU2P ...

AstraZeneca reports higher-than-expected profit, buoyed by blockbuster cancer medicines https://t.co/zEYCjKLXIb ...

In today’s Markets Daily India, we look at retail investors turning net sellers, likely losers from the US pharma tariffs, and key takeaways from large-cap IT earnings. https://t.co/icYTrWEsni ...

Some 22% of American women and 14% of men have taken GLP-1s for weight loss or for chronic conditions such as diabetes. In charts we show the social and economic effects https://t.co/7Pvg34x5gD ...

Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs from [music] Novo Nordisk and Eli Lilly for a copay of just $50 per month.It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened. Well, there' ...